uniQure (NASDAQ:QURE) Price Target Raised to $110.00 at HC Wainwright

uniQure (NASDAQ:QURE) had its price target upped by HC Wainwright from $70.00 to $110.00 in a report published on Monday, MarketBeat.com reports. The firm currently has a buy rating on the biotechnology company’s stock.

Other analysts have also recently issued research reports about the stock. The Goldman Sachs Group increased their price target on shares of uniQure from $13.00 to $56.00 and gave the stock a “neutral” rating in a research report on Thursday, September 25th. Stifel Nicolaus upped their target price on shares of uniQure from $30.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Guggenheim increased their target price on shares of uniQure from $28.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Royal Bank Of Canada restated an “outperform” rating on shares of uniQure in a research note on Wednesday, September 24th. Finally, Mizuho upped their price objective on uniQure from $30.00 to $60.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $71.75.

uniQure Trading Down 3.7%

QURE opened at $52.91 on Monday. uniQure has a 52 week low of $5.03 and a 52 week high of $60.70. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. The business has a fifty day simple moving average of $22.35 and a 200-day simple moving average of $16.67. The firm has a market cap of $2.90 billion, a P/E ratio of -13.50 and a beta of 0.56.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The firm had revenue of $5.26 million for the quarter, compared to analyst estimates of $5.00 million. On average, equities analysts expect that uniQure will post -3.75 earnings per share for the current year.

Insider Buying and Selling at uniQure

In other uniQure news, CFO Christian Klemt sold 15,000 shares of the firm’s stock in a transaction on Friday, September 26th. The stock was sold at an average price of $55.00, for a total value of $825,000.00. Following the sale, the chief financial officer directly owned 217,730 shares in the company, valued at $11,975,150. This trade represents a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 226,316 shares of the company’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the transaction, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. This represents a 25.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 244,316 shares of company stock worth $10,328,181 in the last three months. 4.79% of the stock is currently owned by corporate insiders.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. lifted its position in shares of uniQure by 355.2% during the 1st quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company’s stock worth $3,550,000 after buying an additional 261,323 shares during the last quarter. Mraz Amerine & Associates Inc. acquired a new stake in uniQure during the 1st quarter worth $106,000. Diamond Hill Capital Management Inc. lifted its position in uniQure by 22.8% in the first quarter. Diamond Hill Capital Management Inc. now owns 82,653 shares of the biotechnology company’s stock valued at $876,000 after acquiring an additional 15,333 shares during the last quarter. XTX Topco Ltd boosted its stake in uniQure by 127.3% in the first quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company’s stock valued at $392,000 after acquiring an additional 20,720 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in uniQure by 3.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 279,999 shares of the biotechnology company’s stock valued at $2,968,000 after acquiring an additional 10,019 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.